Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 903Lung Neoplasms 490Small Cell Lung Carcinoma 140Neoplasms 111Melanoma 107Neoplasm Metastasis 105Breast Neoplasms 99Colorectal Neoplasms 94Ovarian Neoplasms 76Carcinoma, Renal Cell 64Pancreatic Neoplasms 62Squamous Cell Carcinoma of Head and Neck 58Mesothelioma 53Stomach Neoplasms 51Head and Neck Neoplasms 47Adenocarcinoma of Lung 46Triple Negative Breast Neoplasms 45Esophageal Neoplasms 40Colonic Neoplasms 40Brain Neoplasms 40Sarcoma 38Mesothelioma, Malignant 38Prostatic Neoplasms 37Urinary Bladder Neoplasms 36Recurrence 30Carcinoma, Transitional Cell 28Uterine Cervical Neoplasms 25Endometrial Neoplasms 25Carcinoma, Hepatocellular 21Carcinoma, Squamous Cell 19

Interventions

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × EGFR Mutated EGFR TKI Naive Metastatic NSCLC × Thoracic × Clear all
NCT02206763 2019-02-01

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sierra Oncology LLC - a GSK company

Phase 1 Terminated
11 enrolled
Thoracic

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡